<DOC>
	<DOCNO>NCT01878981</DOCNO>
	<brief_summary>To generate real world evidence compare clinical outcome patient health-related quality life , result catheter ablation therapy clinical outcome patient health-related quality life result drug therapy China . An economic model construct , use clinical event evidence collect study , China long-term disease progression local disease cost data perform cost-effectiveness evaluation Catheter Ablation versus Drug Therapy AF ( Paroxysmal plus Persistent AF ) patient .</brief_summary>
	<brief_title>Health Economics Evaluation Catheter Ablation Versus Drug Therapy Atrial Fibrillation ( AF ) China</brief_title>
	<detailed_description>The evidence generate study expect help inform medical decision maker clinical economic data therapy AF patient , also provide policy decision maker information consider /used allocate fund AF ablation permit patient access appropriate treatment option AF management .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Patients paroxysmal persistent AF eligible catheter ablation Age 18 80 year Able willing comply pre , post followup testing requirement . Be able sign IRB/EC approve informed consent form . Terminal illness life expectancy le 1 year . New York Heart Association ( NYHA ) Class III IV Previous recipient catheter ablation therapy AF Bradycardia previous recipient pacemaker therapy Previous recipient RFCA ICD therapy Uncontrolled hypertension Recent cardiac event include MI , PCI , valve bypass surgery precede 3 month Patients serious hepatic renal disease Pregnant prepare pregnant one year For drug therapy arm , subject contact via phone subject show his/her disagreement study 30 day window , subject withdrawn study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Catheter Ablation versus Drug Therapy AF China</keyword>
</DOC>